Ignite Creation Date:
2024-07-17 @ 11:02 AM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06501651
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-07-15
First Post:
2024-06-28
Brief Title:
SacubitrilValsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy
Sponsor:
Sichuan Academy of Medical Sciences
Organization:
Sichuan Academy of Medical Sciences
Study Overview
Official Title:
A Prospective Randomized Controlled Multicenter Study of SacubitrilValsartan in the Treatment of Patients With Mild to Moderate Essential Hypertension and Type 2 Diabetic Nephropathy The Hyper-Save Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Hyper-Save
Brief Summary:
This study aims to compare the efficacy and safety of SacubitrilValsartan versus Valsartan in patients with essential hypertension and type 2 diabetic nephropathy over a 12-week treatment period including two treatment groups with a total of 297 eligible subjects randomly assigned in a 21 ratio to either the experimental group or the control groupSubjects will participate in the study through two phases the screening period and the follow-up periodThe primary outcome measure is the change in systolic blood pressure from baseline after 12 weeks of treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None